Currently, there are 191.38M common shares owned by the public and among those 177.81M shares have been available to trade.
The company’s stock has a 5-day price change of -2.21% and 13.68% over the past three months. NKTR shares are trading 135.40% year to date (YTD), with the 12-month market performance up to 169.18% higher. It has a 12-month low price of $0.41 and touched a high of $1.93 over the same period. NKTR has an average intraday trading volume of 1.06 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.15%, 3.74%, and 11.56% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Nektar Therapeutics (NASDAQ: NKTR) shares accounts for 71.60% of the company’s 191.38M shares outstanding.
It has a market capitalization of $253.06M and a beta (3y monthly) value of 0.58. The earnings-per-share (ttm) stands at -$0.90. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.41% over the week and 6.72% over the month.
Analysts forecast that Nektar Therapeutics (NKTR) will achieve an EPS of -0.21 for the current quarter, -0.21 for the next quarter and -0.68 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.26 while analysts give the company a high EPS estimate of -0.26. Comparatively, EPS for the current quarter was -0.24 a year ago. Earnings per share for the fiscal year are expected to increase by 44.88%, and 16.55% over the next financial year.
Looking at the support for the NKTR, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on Nov-05-24, with the firm’s price target at $7. BTIG Research coverage for the Nektar Therapeutics (NKTR) stock in a research note released on September 30, 2024 offered a Buy rating with a price target of $4. TD Cowen on their part issued Outperform rating on November 09, 2023.
